First interchangeable biosimilar launches in the US with a tiny discount on list price
Viatris (formerly known as Mylan and Pfizer’s Upjohn) on Tuesday opened up on the pricing of its interchangeable biosimilar for the insulin Lantus, saying the list price would be set at about $400 for a package of five 3 mL pens, which is about $20 cheaper than the list price for the branded version.
The tiny discount on Semglee’s list price (and the net price discount is expected to be less) offers the first look at how interchangeable biosimilars in the US, meaning they can be substituted for the original insulins without a doctor’s input, might be considered closer cousins to their branded counterparts when it comes to price than other unbranded biosimilars.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
